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A phase II study of Epirubicin in oxaliplatin-
resistant patients with metastatic colorectal
cancer and TOP2A gene amplification
Line S. Tarpgaard1*, Camilla Qvortrup1, Sune B. Nygård2,3, Signe L. Nielsen2, Diana R. Andersen1,
Niels Frank Jensen2, Jan Stenvang2, Sönke Detlefsen4, Nils Brünner2† and Per Pfeiffer1†
Abstract
The overall purpose of this study is to provide proof of concept for introducing the anthracycline epirubicin as an
effective, biomarker-guided treatment for metastatic colorectal cancer (mCRC) patients who are refractory to treatment
with oxaliplatin-based chemotherapy and have TOP2A gene amplification in their tumor cells.
Background: Epirubicin is an anthracycline that targets DNA topoisomerase 2-α enzyme encoded by the TOP2A gene.
It is used for treatment of several malignancies, but currently not in CRC. TOP2A gene amplifications predict improved
efficacy of epirubicin in patients with breast cancer and thus could be an alternative option for patients with CRC and
amplified TOP2A gene. We have previously analysed the frequency of TOP2A gene aberrations in CRC and found that
46.6 % of these tumors had TOP2A copy gain and 2.0 % had loss of TOP2A when compared to adjacent normal tissue.
The TOP2A gene is located on chromosome 17 and when the TOP2A/CEN-17 ratio was applied to identify tumors with
gene loss or amplifications, 10.5 % had a ratio ≥ 1.5 consistent with gene amplification and 2.6 % had a ratio ≤ 0.8
suggesting gene deletions. Based on these observations and the knowledge gained from treatment of breast cancer
patients, we have initiated a prospective clinical, phase II protocol using epirubicin (90 mg/m2 iv q 3 weeks) in mCRC
patients, who are refractory to treatment with oxaliplatin.
Methods/Design: The study is an open label, single arm, phase II study, investigating the efficacy of epirubicin in
patients with oxaliplatin refractory mCRC and with a cancer cell TOP2A/CEN-17 ratio ≥ 1.5. TOP2A gene amplification
measured by fluorescence in situ hybridization. A total of 25 evaluable patients (15 + 10 in two steps) will be included
(Simon’s two-stage minimax design). Every nine weeks, response is measured by computed tomography imaging and
evaluated according to RECIST 1.1. The primary end-point of the study is progression-free survival.
Trial registration: Eudract no. 2013-001648-79.
Background
Colorectal cancer (CRC) is a major health problem since
it is among the five most prevalent cancers [1, 2]. Over
the last decade, the use of novel treatment modalities
and complex treatment strategies in terms of optimized
surgery, adjuvant chemotherapy, and novel targeted
biological agents have contributed to significant im-
provement of outcome of the entire population of
patients with CRC. However, only three cytotoxic drugs
(fluorouracil (5-FU), oxaliplatin and irinotecan) are
recommended as standard treatment in patients with
metastatic CRC (mCRC). In Europe, the routine clinical
management of patients with primary CRC involves
adjuvant treatment with 5-FU/Leucovorin (LV) and
oxaliplatin (FOLFOX, FLOX or XELOX) given to high-
risk patients [3–6]. In the treatment of mCRC, patients
who have yet not received oxaliplatin will often be
offered FOLFOX, FLOX or XELOX, followed by 5-FU/LV
and irinotecan (FOLFIRI, FLIRI or XELIRI) at progression,
or vice versa [7–10]. Chemotherapy may be combined
with the EGF-receptor targeting antibodies cetuximab or
panitumumab in patients with RAS wild type tumors
[11–14], while patients with RAS mutated tumors often
will receive the VEGF targeting antibody bevacizumab
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[15, 16]. The objective response rate to first-line sys-
temic treatment of mCRC patients approximates 50 %
[10, 17]. However, only 10 % of mCRC patients will ob-
tain objective response during second-line treatment
[10], suggesting that there is a high degree of cross-
resistance between the used drugs. Improvements in
mCRC treatment may be achieved through the develop-
ment of novel drugs with new molecular mechanisms
of action and thus lack of cross-resistance with cur-
rently used drugs. However, drug development is ex-
pensive (estimated cost is 1 Bill USD per drug), takes a
long time (12–15 years) and the risk of failure in late
stage clinical trials is extremely high. An alternative to
the drug development approach is to search for novel
predictive biomarkers that can guide personalized treat-
ment and thereby select the right drug for the right pa-
tient at the right time. Using predictive biomarkers will
increase the therapeutic index and avoid side effects
among the many patients who will not benefit from the
treatment. A third way to address these medical prob-
lems is to test whether drugs being used in some other
cancer types might have beneficial effects also in CRC.
However, with an expected relatively low response rate,
such drugs should only be used together with companion
diagnostics allowing for a pre-treatment selection of pa-
tients with the highest likelihood of obtaining benefit from
the treatment. This third approach is called biomarker
guided repurposing and is the foundation for the present
protocol, where we investigate whether epirubicin has a
beneficial effect in oxaliplatin resistant mCRC patients
with TOP2A gene amplification.
Epirubicin and TOP2A
The anthracycline epirubicin exerts its antitumor effects
by interference with the synthesis and function of DNA
and is most active in the S-phase of the cell cycle [18]. It
is metabolized in the liver and primarily eliminated in
the bile. The main molecular target of epirubicin is the
DNA topoisomerase 2-α enzyme (Top2α) that plays a
key role in maintaining the topological status of chromo-
somes during DNA replication and transcription. During
DNA transcription, Top2α removes DNA supercoiling,
and at the end of DNA replication, Top2α is essential
for chromosome condensation and segregation. In this
process, Top2α reversibly binds and cleaves both com-
plementary DNA strands forming what is called a Top2
cleaving complex (Top2cc). Epirubicin leads to entrap-
ment of Top2α in the Top2CC and thereby prevents
religation of the cleaved DNA strands, which ultimately
leads to DNA damage. Apart from this, epirubicin also
interferes with a broad range of DNA processes through
DNA intercalation [19].
TOP2A amplification predicts improved efficacy to
epirubicin in patients with breast cancer [20, 21] and
thus could be an alternative option to irinotecan-based
therapy in patients with CRC and TOP2A amplification
who relapsed on oxaliplatin containing chemotherapy.
We have previously established irinotecan (SN-38, the
active metabolite of irinotecan) resistant CRC cell lines,
and these CRC cells were also resistant to epirubicin
[22]. In contrast, our SN-38 resistant CRC cells were
also resistant to epirubicin whereas our oxaliplatin re-
sistant CRC cell lines retained sensitivity to epirubicin
[Niel Frank Jensen et al. Unpublished observations]. In
another study we analysed the frequency of TOP2A ab-
errations in CRC tissue from 153 primary stage III CRC
tumors and found that 46.6 % had TOP2A copy gain and
2.0 % TOP2A loss, when compared to adjacent normal
tissue [23]. When the TOP2A/CEN-17 ratio was applied
to identify tumors with gene loss or amplifications, 16
(10.5 %) had a ratio ≥ 1.5, consistent with gene amplifi-
cation and 4 (2.6 %) had a ratio ≤ 0.8, suggesting gene
deletion.
Design/methods
Design
The study is an open label, single arm, phase II study,
investigating the efficacy of epirubicin in patients with
oxaliplatin refractory mCRC and a cancer cell TOP2A/
CEN-17 ratio ≥ 1.5. A second aim is the collection of
relevant tumor and blood material for subsequent bio-
marker studies.
Inclusion criteria
To be eligible for inclusion, patients must provide writ-
ten informed consent. All patients must be above the
age of 18 years, have WHO performance status 0–2, and
a life expectancy of at least 3 months. Furthermore, pa-
tients must have histologically verified, non-resectable,
oxaliplatin resistant mCRC i.e. progression during or
after oxaliplatin-based therapy (at least 2 months of
oxaliplatin-based palliative therapy or at least 4 months
of adjuvant oxaliplatin-based therapy). Moreover, FFPE
tumor tissue blocks (primary tumor biopsy/resection speci-
men or biopsy/resection specimen from a metastatic lesion)
must be available for fluorescence in situ hybridization
(FISH) analysis of the TOP2A/CEN-17 ratio and this ratio
has to be ≥ 1.5.
Treatment
Drug/dosage: Epirubicin 90 mg/m2 day 1 administration
via fast running infusion of 0.9 % sodium chloride every
21-day. Treatment will continue until maximum cumu-
lative dose of Epirubicin = 900 mg/m2, unacceptable tox-
icity, progressive disease at computer tomography (CT)
scan according to RECIST version 1.1 or patients wish of
ending treatment. Before start of treatment a baseline
CT scan will be performed, and a new CT scan will
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be performed after every third series of epirubicin to
monitor treatment response.
Ethics
The study will be conducted in compliance with the
protocol and in accordance with the ethical principles
put forward in the second Declaration of Helsinki and in
accordance with good clinical practice (GCP) rules. The
trial was approved by the Ethics Committee of Region
Syddanmark (2013-001648-79/ S-20130042) and by the
Danish Medical Authority (Eudract no. 2013-001648-79).
Study objectives
The primary end-point of the study is progression-free
survival (PFS), defined as time from the first infusion of
epirubicin to the first documented disease progression,
according to RECIST version 1.1. Secondary end-points
include overall survival (OS), response rate (RR), toxicity,
and validation of tissue inhibitor of metalloproteinase-1
(TIMP-1) measured in plasma and immunohistochemi-
cally in tumor tissue, as biomarker for anthracycline
sensitivity/resistance [24]. Additionally, the relationship
between TOP2A and TOP1 gene amplifications will be
studied [25].
Statistics
The number of evaluable patients (the sample size) is
based on Simon’s two stages Mini-max design [26]. This
design ensures early study termination if there is insuffi-
cient effect. Patients will be evaluated with CT scans
every 9 weeks. In randomized trials on second-line therapy,
PFS is around 4 months. A tumor control rate less than
10 % after 4 months (at the time of the second evaluation
CT scan) is not clinically relevant. Assuming a significance
level at 0.05 (α = 0.05) and a power at 80 % (β = 0.20) it can
be calculated, that 15 patients should be included in the
first part of the study. The enrolment will continue until
15 patients have completed the second CT scan or experi-
enced progressive disease. If none out of the first 15 con-
secutive patients achieve stable disease at the second CT
scan (i.e. after 6 courses of epirubicin), we will reject our
hypotheses and close the study after the first stage of
accrual. If one or more patients achieve tumor control
(partial response or stable disease) at the second scan, an
additional 10 patients will be accrued in the second stage.
If 5 out of 25 patients achieve tumor control after six
courses of therapy, a tumor control rate of 30 % cannot be
rejected, and it will be concluded that the treatment is
effective enough to continue with future studies.
We will use non-parametric methods for calculation of
patient characteristics, side effects and disease control.
PFS and OS will be calculated and reported as median
survival (Kaplan-Meier method).
Methods
The TOP2A FISH pharmDx™ Kit (Dako, Glostrup,
Denmark) will be used according to the manufacturer’s
instructions, as previously reported [23]. For every pa-
tient tumor sample, TOP2A and CEN-17 signals will be
counted in 60 non-overlapping malignant cells, and a
TOP2A/CEN-17 ratio will be calculated as the total
counted number of TOP2A signals divided by the total
counted number of CEN-17 signals. TOP2A FISH ana-
lysis will be performed on archived FFPE tumor tissues
obtained from either the primary tumor (at time of diag-
nosis or obtained from the surgical resection specimen) or
from a metastatic lesion (biopsy or resection specimen).
Discussion
The number of treatment options in patients with
mCRC is still very limited. Response rates decrease dra-
matically with time, while the patients proceed in the
treatment lines. New and non-cross resistant treatment
options are urgently needed, and biomarkers predictive
of response to chemotherapeutic treatments are totally
lacking. Studies on breast cancer patients indicate that
amplification and possibly deletion of TOP2A is predictive
of response to epirubicin [20, 21]. Data on TOP2A aberra-
tions in CRC are sparse, with reported TOP2A amplifica-
tion rates ranging from 2.2 to 46.6 % in studies using
different analytical methods [23, 27, 28]. In a study of the
frequency of TOP2A gene aberrations in CRC tissue, we
found that a total of 10.5 % of the patients had a TOP2A/
CEN-17 ratio ≥ 1.5, which is compatible with TOP2A
amplification [23]. Previous studies have investigated the
effect of epirubicin in the entire unselected group of pa-
tients with mCRC, but found that this treatment had
lower impact than oxaliplatin- or irinotecan-based treat-
ment options [18, 29–31]. Taken together, those data led
to the hypothesis that re-purposing epirubicin to patients
with mCRC and TOP2A gene amplification may represent
a valid treatment offer to a subset of mCRC patients.
Hence, the aim of this clinical study is to take a further
step towards personalized mCRC treatment. If epirubicin
should prove to be effective in patients with increased
TOP2A gene copy numbers, this may lead to a novel per-
sonalized treatment option for patients with mCRC.
This study differs from the standard treatment strategy
for mCRC, where the patients often will be offered
irinotecan-based therapy after failure to oxaliplatin-
based therapy or vice versa. Median PFS of this stand-
ard treatment is approximately 2 months, and 75 % of
the patients will experience progressive disease after
4 months of treatment [10]. In the present phase II proto-
col with pre-selected patients, we expect that 30 % will have
objective response after the first 4 months of treatment,
thereby achieving an increased median PFS. All patients
will be evaluated every 9 weeks, enabling a quick change in
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treatment strategy if a patient experiences disease progres-
sion during epirubicin treatment [32, 33]. Carefully planned
and closely monitored “window of opportunity” phase II
studies are feasible and ethically acceptable in mCRC pa-
tients, and may have the advantage to determine potential
efficacy of novel agents without placing the patients at risk.
In the present study, close monitoring of efficacy every
9 weeks will ensure that this novel treatment line with
epirubicin will be offered without further delay in case of
progression during epirubicin treatment, with respect to
any future treatment option.
The statistical basis for the protocol is based on the
fact that we expect a response rate of 30 % in this sub-
population of patients with TOP2A aberrations, which is
significantly better than the typical second line treatment
these patients will be offered, which usually has response
rates of 10 %. In conclusion, if the objectives of this
study protocol are met, the expected 10 % of mCRC pa-
tients with a TOP2A/CEN-17 ratio ≥ 1.5 will be offered
an extra line of effective treatment, which may lead to
an overall improved survival in this subgroup of mCRC
patients.
Trial status
A total of 120 patients have been screened for TOP2A
levels and we have found 14 patients (12 %) to have a
TOP2A/CEN-17 ratio ≥ 1.5 in primary tumor, a metastatic
lesion or both. To date 3 patients have been included and
initiated treatment with epirubicin.
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